MedPath

Coagulation Factor IX (Recombinant)

Generic Name
Coagulation Factor IX (Recombinant)
Brand Names
Benefix, Idelvion, Ixinity, Rixubis, BeneFIX
Drug Type
Biotech
Chemical Formula
-
CAS Number
181054-95-5
Unique Ingredient Identifier
382L14738L
Background

Recombinant Coagulation Factor IX is a purified Factor IX glycoprotein produced by recombinant DNA technology. It has a primary amino acid sequence that is identical to the Ala148 allelic form of human factor IX, and has structural and functional characteristics similar to those of endogenous factor IX. It is not derived from human blood (unlike human Factor IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell medium that is then processed and purified for use as a pharmaceutical agent.

Recombinant Factor IX is indicated for the control and prevention of bleeding episodes in adult and pediatric patients with congenital factor IX deficiency (Hemophilia B).

Indication

For treatment of hemophilia (Christmas disease).

Associated Conditions
Bleeding, Hemophilia B, Perioperative bleeding caused by Hemophilia B
Associated Therapies
-
Clinical Trials
Related News
openpr.com
·

Hemophilia B Treatment Market 2034: EMA, PDMA, FDA Approvals

Hemophilia B market to grow significantly by 2034, driven by gene therapies like HEMGENIX and BEQVEZ, priced at $3.5 million each. Key companies include Centessa Pharmaceuticals, Sanofi, Pfizer, and Novo Nordisk. Market dynamics influenced by increasing prevalence, prophylactic treatment focus, and pipeline advancements.
finance.yahoo.com
·

Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug

XOMA Royalty announces FDA approval of MIPLYFFA™, the first therapy for NPC, entitling XOMA to a mid-single digit royalty on sales and up to $52.6 million in milestones, making it the sixth commercial asset in their portfolio.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy